Adjuvant Mitotane Therapy of Adrenal Cancer — Use and Controversy

Adrenocortical carcinoma is a rare, highly malignant neoplasm with an incidence of 2 cases per 1 million population per year worldwide, representing 0.2% of all cases of cancer. Several treatment strategies in patients with advanced disease have resulted in temporary or partial tumor regression, yet very few patients attain long-term survival. Assessing the effectiveness of most published treatment protocols has been difficult, since most series have been limited by the inclusion of relatively few subjects, with tumors at various stages and grades. Several drug regimens have been used, and multiple treatments have been administered in various sequences. In addition, the . . .